Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.

scientific article

Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/10543400902800478
P698PubMed publication ID19384686

P2093author name stringCong Chen
Robert A Beckman
P2860cites workA flexible design for multiple armed screening trialsQ33181833
Design issues of randomized phase II trials and a proposal for phase II screening trialsQ40385205
Decision-theoretic designs for pre-phase II screening trials in oncologyQ40669546
The sample size for a clinical trial: a Bayesian-decision theoretic approachQ43544194
Sample size calculation for a proof of concept studyQ44202724
New designs for phase 2 clinical trialsQ44298388
Optimal two-stage designs for phase II clinical trialsQ46412217
P433issue3
P921main subjectphase II clinical trialQ42824440
P304page(s)424-436
P577publication date2009-01-01
P1433published inJournal of Biopharmaceutical StatisticsQ15764587
P1476titleOptimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.
P478volume19

Reverse relations

cites work (P2860)
Q39489357A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk
Q44644308A portfolio-based approach to optimize proof-of-concept clinical trials
Q33433456Current issues in oncology drug development, with a focus on Phase II trials
Q38660962Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution.
Q36925422Decision-theoretic designs for small trials and pilot studies: A review
Q38209093Emerging drugs for neuropathic pain
Q47912286Evaluation of early efficacy endpoints for proof-of-concept trials
Q41489822Evaluation of program success for programs with multiple trials in binary outcomes
Q37940788Integrating predictive biomarkers and classifiers into oncology clinical development programmes
Q37353962New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs
Q37481946PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
Q38578613Translating predictive biomarkers within oncology clinical development programs

Search more.